查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600551

品牌非專利市場：按產品類型、藥物類型、給藥途徑、適應症、分銷管道 - 全球預測 2025-2030

Branded Generics Market by Product (Trade Named Generics, Value-Added), Drug Type (Alkylating Agents, Anti-depressants, Anti-epileptics), Route of Administration, Indication, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，品牌非專利市場價值為4,323億美元，預計到2024年將達到4,942.9億美元，複合年成長率為14.66%，到2030年將達到11,264.3億美元。

品牌非專利是指製藥公司以品牌名稱銷售的專利到期藥物，為學名藥​​提供了一種經濟高效的替代品，同時保持了品牌忠誠度優勢。需要平衡負擔能力和品質保證，這使得它在醫療費用昂貴的地區變得至關重要。這些藥物通常具有多種治療應用，用於從慢性疾病到急性護理的廣泛治療，並擁有廣泛的最終用戶，包括醫療保健提供者、醫院和個人消費者。推動品牌非專利成長的關鍵因素包括慢性病盛行率的增加、對負擔得起的藥物的需求不斷成長以及醫療保健機會有限的新興市場的重要性日益增加。最新的商機在於利用數位行銷管道，透過專注於新興市場的策略聯盟和收購來提高品牌影響力並擴大分銷網路。然而，市場面臨嚴格的法規環境、激烈的價格競爭和智慧財產權問題等挑戰，這可能會阻礙成長。醫療保健政策的不斷演變也存在限制，這可能會影響市場進入和藥品價格。創新可以探索生物相似藥和個人化醫療的發展，使品牌能夠透過專注於患者特定的解決方案來脫穎而出。此外，品牌可以透過投資先進的藥物輸送機制和數位健康監測工具來獲得競爭優勢。品牌非專利市場競爭溫和，眾多全球和地區公司爭奪市場佔有率，需要持續創新和以客戶為導向的策略。為了實現永續成長，我們建議投資研發、最佳化供應鏈效率、優先考慮新興打入市場策略並積極應對監管變化。營運敏捷性和強大的品牌差異化對於克服限制和抓住市場機會至關重要。

主要市場統計
基準年[2023] 4323億美元
預測年份 [2024] 4942.9億美元
預測年份 [2030] 1,126,430 百萬美元
複合年成長率（%） 14.66%

市場動態：揭示快速發展的品牌非專利市場的關鍵市場洞察

供需的動態交互作用正在改變品牌非專利市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 需要使用學名藥的慢性疾病流行
    • 重磅藥物專利到期增加以及對具有成本效益的替代品的需求增加
  • 市場限制因素
    • 對品牌學名藥品質差異的擔憂
  • 市場機會
    • 新的生物等效性測試和市場參與企業為擴大品牌非專利業務所做的努力
  • 市場挑戰
    • 訴訟問題及新藥價格下跌相關問題

波特的五力：駕馭品牌非專利市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解品牌非專利市場的外部影響

外部宏觀環境因素在塑造品牌非專利市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解品牌非專利市場的競爭狀況

對品牌非專利市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 品牌非專利市場定位矩陣供應商績效評估

FPNV定位矩陣是評估品牌非專利市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 需要使用學名藥的慢性病的流行
      • 重磅藥物專利到期的增加和對具有成本效益的替代品的需求增加
    • 抑制因素
      • 對品牌學名藥品質差異的擔憂
    • 機會
      • 新的生物等效性研究和市場參與者擴大品牌非專利業務的努力
    • 任務
      • 與訴訟問題和品牌藥價格下跌相關的問題
  • 市場區隔分析
    • 產品：大量採用付加品牌非專利可帶來額外好處
    • 藥物類型：抗高血壓藥物通常用於治療高血壓。
    • 給藥途徑：口服給藥因其作用時間長而被廣泛採用。
    • 適應症：品牌非專利在胃腸道和神經系統疾病的使用激增
    • 分銷管道：品牌非專利線上分銷管道的演變
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 品牌非專利市場：依產品

  • 產品名稱學名藥
  • 付加

第7章 品牌非專利市場藥品（按類型）

  • 烷化劑
  • 抗憂鬱症
  • 抗癲癇藥
  • 抗高血壓藥
  • 抗精神病藥物
  • 抗代謝物
  • 荷爾蒙
  • 降血脂藥

第8章 品牌非專利市場：依管理途徑

  • 口服
  • 胃腸外的
  • 話題

第9章以適應症分類的品牌非專利市場

  • 急性和慢性疼痛
  • 心血管疾病
  • 皮膚病
  • 消化系統疾病
  • 神經系統疾病
  • 腫瘤學

第 10 章 品牌非專利市場：按分銷管道

  • 離線
    • 醫院藥房
    • 零售藥房
  • 線上

第11章 美洲品牌非專利市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太品牌非專利市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲的品牌非專利市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Vyvanse非專利獲 FDA核准
    • 藥聯會與學名藥協會更新學名藥定價協議
    • Amneal 推出經批准的 Xyrem（奧昔巴特鈉）非專利，並獲得 FDA核准5 種複合非專利
    • Ajanta Pharma 旨在擴大快速成長的亞洲和非洲地區的業務
    • 雷迪博士進軍國內市場學名藥業務
    • Sun Pharma 推出輝瑞重磅抗癌藥物的非專利藥
    • Zentiva 完成對西班牙 Tiromed 的主要產品收購
    • Cipla推出“Easy Lux L”，一種緩解便秘的無糖口服乳液瀉藥
    • ProCaps Group 從 Advent International 收購 Grupo Somar

公司名單

  • Dr. Reddy's Laboratories Ltd.
  • Lupin Limited
  • Viatris Inc.
  • Sandoz International GmbH by Novartis AG
  • Bausch Health Companies Inc.
  • GlaxoSmithKline PLC
  • Amneal Pharmaceuticals LLC
  • Eris Lifesciences Limited
  • Alkem Laboratories Ltd.
  • Cipla Limited
  • Zentiva Group, as
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • Endo International PLC
  • Aurobindo Pharma Limited
  • AstraZeneca PLC
  • Eva Pharma
  • Hetero Drugs Limited
  • Abbott Laboratories
  • Glenmark Pharmaceuticals Limited
  • Fresenius Kabi AG
  • Pfizer Inc.
  • Aspen Pharmacare Holdings Limited
  • Sun Pharmaceutical Industries Ltd.
  • Ajanta Pharma Ltd.
  • Apotex Inc.
  • Bristol-Myers Squibb Company
  • Sanofi SA
  • Micro Labs Limited
  • Torrent Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-A26E0E57422E

The Branded Generics Market was valued at USD 432.30 billion in 2023, expected to reach USD 494.29 billion in 2024, and is projected to grow at a CAGR of 14.66%, to USD 1,126.43 billion by 2030.

Branded generics refer to off-patent drugs that are sold under a brand name by pharmaceutical companies, offering a cost-effective alternative to generic drugs while retaining brand loyalty advantages. Their necessity arises from the balance they offer between affordability and quality assurance, making them integral in regions where healthcare costs are critical. These drugs are typically applied across multiple therapeutic areas, used in treatments from chronic diseases to acute care, with end-users ranging from healthcare providers, hospitals, and individual consumers. Key factors driving the growth of branded generics include an increase in the prevalence of chronic diseases, rising demand for affordable medication, and expansion in emerging markets where healthcare access is limited yet increasingly crucial. Latest opportunities lie in leveraging digital marketing channels to enhance brand presence and focusing on strategic partnerships or acquisitions in emerging markets to widen distribution networks. However, the market faces challenges such as stringent regulatory environments, fierce price competition, and intellectual property concerns, which can hinder growth. Limitations also stem from the constant evolution of healthcare policies that can affect market access and drug pricing. Innovations could explore the development of biosimilars and personalized medicine as brands could differentiate by focusing on patient-specific solutions. Additionally, investing in advanced drug delivery mechanisms and digital health monitoring tools could provide brands a competitive edge. The nature of the branded generics market is moderately competitive, with numerous global and regional players striving for market share, necessitating continual innovation and customer-oriented strategies. For sustained growth, companies are recommended to invest in R&D, optimize supply chain efficiency, and prioritize emerging market entry strategies while adapting to regulatory changes proactively. The need for both operational agility and strong brand differentiation is paramount in capturing market opportunities while navigating the limitations.

KEY MARKET STATISTICS
Base Year [2023] USD 432.30 billion
Estimated Year [2024] USD 494.29 billion
Forecast Year [2030] USD 1,126.43 billion
CAGR (%) 14.66%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Branded Generics Market

The Branded Generics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of chronic diseases necessitating the use of generic medications
    • Increasing patent expiration for blockbuster drugs and the need for cost-effective alternatives
  • Market Restraints
    • Concerns associated with quality variations in branded generic medications
  • Market Opportunities
    • Novel bioequivalence studies and efforts by market players to expand branded generics business
  • Market Challenges
    • Litigation issues and issues related to price erosion of innovator drugs

Porter's Five Forces: A Strategic Tool for Navigating the Branded Generics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Branded Generics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Branded Generics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Branded Generics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Branded Generics Market

A detailed market share analysis in the Branded Generics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Branded Generics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Branded Generics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Branded Generics Market, highlighting leading vendors and their innovative profiles. These include Dr. Reddy's Laboratories Ltd., Lupin Limited, Viatris Inc., Sandoz International GmbH by Novartis AG, Bausch Health Companies Inc., GlaxoSmithKline PLC, Amneal Pharmaceuticals LLC, Eris Lifesciences Limited, Alkem Laboratories Ltd., Cipla Limited, Zentiva Group, a.s., Nichi-Iko Pharmaceutical Co., Ltd., Endo International PLC, Aurobindo Pharma Limited, AstraZeneca PLC, Eva Pharma, Hetero Drugs Limited, Abbott Laboratories, Glenmark Pharmaceuticals Limited, Fresenius Kabi AG, Pfizer Inc., Aspen Pharmacare Holdings Limited, Sun Pharmaceutical Industries Ltd., Ajanta Pharma Ltd., Apotex Inc., Bristol-Myers Squibb Company, Sanofi S.A., Micro Labs Limited, Torrent Pharmaceuticals Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Branded Generics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Trade Named Generics and Value-Added.
  • Based on Drug Type, market is studied across Alkylating Agents, Anti-depressants, Anti-epileptics, Anti-hypertensive, Anti-psychotics, Antimetabolites, Hormones, and Lipid Lowering Drugs.
  • Based on Route of Administration, market is studied across Oral, Parenteral, and Topical.
  • Based on Indication, market is studied across Acute & Chronic Pain, Cardiovascular Diseases, Dermatological Diseases, Gastrointestinal Diseases, Neurological Diseases, and Oncology.
  • Based on Distribution Channel, market is studied across Offline and Online. The Offline is further studied across Hospital Pharmacy and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic diseases necessitating the use of generic medications
      • 5.1.1.2. Increasing patent expiration for blockbuster drugs and the need for cost-effective alternatives
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with quality variations in branded generic medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Novel bioequivalence studies and efforts by market players to expand branded generics business
    • 5.1.4. Challenges
      • 5.1.4.1. Litigation issues and issues related to price erosion of innovator drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Significant adoption of value-added branded generics due to their additional advantages
    • 5.2.2. Drug Type: High usage of anti-hypertensive for treating high blood pressure
    • 5.2.3. Route of Administration: Wide adoption of oral route due to their longer duration of action
    • 5.2.4. Indication: Burgeoning utilization of branded generics for gastrointestinal diseases and neurological diseases
    • 5.2.5. Distribution Channel: Evolving online distribution channels for branded generics
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Branded Generics Market, by Product

  • 6.1. Introduction
  • 6.2. Trade Named Generics
  • 6.3. Value-Added

7. Branded Generics Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Alkylating Agents
  • 7.3. Anti-depressants
  • 7.4. Anti-epileptics
  • 7.5. Anti-hypertensive
  • 7.6. Anti-psychotics
  • 7.7. Antimetabolites
  • 7.8. Hormones
  • 7.9. Lipid Lowering Drugs

8. Branded Generics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral
  • 8.4. Topical

9. Branded Generics Market, by Indication

  • 9.1. Introduction
  • 9.2. Acute & Chronic Pain
  • 9.3. Cardiovascular Diseases
  • 9.4. Dermatological Diseases
  • 9.5. Gastrointestinal Diseases
  • 9.6. Neurological Diseases
  • 9.7. Oncology

10. Branded Generics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Offline
    • 10.2.1. Hospital Pharmacy
    • 10.2.2. Retail Pharmacy
  • 10.3. Online

11. Americas Branded Generics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Branded Generics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Branded Generics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Vyvanse Generics Approved by FDA
    • 14.3.2. Pharmaceutical Alliance, Generic Pharmaceutical Association Renew Generic Drug Pricing Agreement
    • 14.3.3. Amneal Launches Authorized Generic for Xyrem (sodium oxybate) and Receives FDA Approval for Five Complex Generics
    • 14.3.4. Ajanta Pharma looks to expand ops in high-growth Asian, African geographies
    • 14.3.5. Dr Reddy's Enters Trade Generics Business In Domestic Market
    • 14.3.6. Sun Pharma Launches Generic Version of Pfizer's Blockbuster Cancer Drug
    • 14.3.7. Zentiva Completes Major Product Acquisition From Tillomed Spain
    • 14.3.8. Cipla Launches 'Easylax L',A Sugar-Free Oral Emulsion Laxative For Constipation Relief
    • 14.3.9. Procaps Group to Acquire Grupo Somar from Advent International

Companies Mentioned

  • 1. Dr. Reddy's Laboratories Ltd.
  • 2. Lupin Limited
  • 3. Viatris Inc.
  • 4. Sandoz International GmbH by Novartis AG
  • 5. Bausch Health Companies Inc.
  • 6. GlaxoSmithKline PLC
  • 7. Amneal Pharmaceuticals LLC
  • 8. Eris Lifesciences Limited
  • 9. Alkem Laboratories Ltd.
  • 10. Cipla Limited
  • 11. Zentiva Group, a.s.
  • 12. Nichi-Iko Pharmaceutical Co., Ltd.
  • 13. Endo International PLC
  • 14. Aurobindo Pharma Limited
  • 15. AstraZeneca PLC
  • 16. Eva Pharma
  • 17. Hetero Drugs Limited
  • 18. Abbott Laboratories
  • 19. Glenmark Pharmaceuticals Limited
  • 20. Fresenius Kabi AG
  • 21. Pfizer Inc.
  • 22. Aspen Pharmacare Holdings Limited
  • 23. Sun Pharmaceutical Industries Ltd.
  • 24. Ajanta Pharma Ltd.
  • 25. Apotex Inc.
  • 26. Bristol-Myers Squibb Company
  • 27. Sanofi S.A.
  • 28. Micro Labs Limited
  • 29. Torrent Pharmaceuticals Ltd.
  • 30. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. BRANDED GENERICS MARKET RESEARCH PROCESS
  • FIGURE 2. BRANDED GENERICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. BRANDED GENERICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. BRANDED GENERICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRANDED GENERICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BRANDED GENERICS MARKET DYNAMICS
  • TABLE 7. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY TRADE NAMED GENERICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY VALUE-ADDED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRANDED GENERICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-DEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-HYPERTENSIVE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-PSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BRANDED GENERICS MARKET SIZE, BY HORMONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BRANDED GENERICS MARKET SIZE, BY LIPID LOWERING DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BRANDED GENERICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BRANDED GENERICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BRANDED GENERICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BRANDED GENERICS MARKET SIZE, BY ACUTE & CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BRANDED GENERICS MARKET SIZE, BY DERMATOLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BRANDED GENERICS MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BRANDED GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. CHINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. INDIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. INDONESIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. JAPAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. MALAYSIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SINGAPORE BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. TAIWAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. THAILAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. VIETNAM BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. DENMARK BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. EGYPT BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. FINLAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. FRANCE BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. GERMANY BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. ISRAEL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. ITALY BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 213. NIGERIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. NORWAY BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. POLAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. QATAR BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. RUSSIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 255. SPAIN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 260. SWEDEN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 261. SWEDEN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 266. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 272. TURKEY BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 273. TURKEY BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 286. BRANDED GENERICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 287. BRANDED GENERICS MARKET, FPNV POSITIONING MATRIX, 2023